SMT201800342T1 - Modulatore pirrolidinici di gpr40 per il trattamento di malattie come il diabete - Google Patents

Modulatore pirrolidinici di gpr40 per il trattamento di malattie come il diabete

Info

Publication number: SMT201800342T1
Authority: SM; San Marino
Prior art keywords: diabetes; diseases; treatment; gpr40 modulators; pyrrolidine
Prior art date: 2014-05-07

Application number

SM20180342T

Other languages

English (en)

Inventor

Elizabeth A Jurica

Zhenqiu Hong

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-07

Filing date

2015-05-06

Publication date

2018-09-13

2015-05-06 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2018-09-13 Publication of SMT201800342T1 publication Critical patent/SMT201800342T1/it

Links

RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 3
206010012601 diabetes mellitus Diseases 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SM20180342T 2014-05-07 2015-05-06 Modulatore pirrolidinici di gpr40 per il trattamento di malattie come il diabete SMT201800342T1 (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461989651P	2014-05-07	2014-05-07
PCT/US2015/029409 WO2015171722A1 (en)	2014-05-07	2015-05-06	Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EP15723095.4A EP3140296B1 (en)	2014-05-07	2015-05-06	Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (1)

Publication Number	Publication Date
SMT201800342T1 true SMT201800342T1 (it)	2018-09-13

Family

ID=53181359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20180342T SMT201800342T1 (it)	2014-05-07	2015-05-06	Modulatore pirrolidinici di gpr40 per il trattamento di malattie come il diabete

Country Status (33)

Country	Link
US (4)	US9873679B2 (it)
EP (1)	EP3140296B1 (it)
JP (1)	JP6483156B2 (it)
KR (1)	KR102336370B1 (it)
CN (1)	CN106458976B (it)
AR (1)	AR100328A1 (it)
AU (1)	AU2015256120B2 (it)
BR (1)	BR112016024936A2 (it)
CA (1)	CA2948161C (it)
CL (1)	CL2016002809A1 (it)
CY (1)	CY1120340T1 (it)
DK (1)	DK3140296T3 (it)
EA (1)	EA033250B1 (it)
ES (1)	ES2674531T3 (it)
HR (1)	HRP20180641T1 (it)
HU (1)	HUE039288T2 (it)
IL (1)	IL248668B (it)
MA (1)	MA39427B1 (it)
MX (1)	MX378160B (it)
MY (1)	MY181959A (it)
NZ (1)	NZ727146A (it)
PE (1)	PE20161363A1 (it)
PH (1)	PH12016502034B1 (it)
PL (1)	PL3140296T3 (it)
PT (1)	PT3140296T (it)
RS (1)	RS57170B1 (it)
SG (1)	SG11201609170UA (it)
SI (1)	SI3140296T1 (it)
SM (1)	SMT201800342T1 (it)
TN (1)	TN2016000444A1 (it)
TR (1)	TR201809633T4 (it)
TW (1)	TWI659951B (it)
WO (1)	WO2015171722A1 (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2671402T3 (es) *	2014-05-07	2018-06-06	Bristol-Myers Squibb Company	Moduladores de pirrolidina GPR40 para el tratamiento de enfermedades tales como diabetes
EP3140296B1 (en) *	2014-05-07	2018-04-11	Bristol-Myers Squibb Company	Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
JP7086942B2 (ja)	2016-09-12	2022-06-20	インテグラルヘルス，インコーポレイテッド	Ｇｐｒ１２０モジュレーターとして有用な単環式化合物
WO2018049328A1 (en)	2016-09-12	2018-03-15	Numerate, Inc.	Bicyclic compounds useful as gpr120 modulators
WO2018181847A1 (ja) *	2017-03-31	2018-10-04	武田薬品工業株式会社	芳香環化合物
BR102018007822A2 (pt)	2017-04-20	2018-11-06	Gilead Sciences, Inc.	composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN110772636B (zh) *	2017-08-21	2021-03-16	武汉大学	Gpr31抑制剂在制备治疗心脏缺血再灌注损伤及相关疾病药物中的应用
CR20200347A (es)	2018-02-13	2020-09-23	Gilead Sciences Inc	Inhibidores pd-1/pd-l1
TWI712412B (zh)	2018-04-19	2020-12-11	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
SG11202012425QA (en)	2018-07-13	2021-01-28	Gilead Sciences Inc	Pd-1/pd-l1 inhibitors
WO2020086556A1 (en)	2018-10-24	2020-04-30	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
CA3121202A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
AU2022291768A1 (en)	2021-06-16	2023-11-30	Celgene Corporation	Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
CN116283699B (zh) *	2023-03-02	2025-02-11	遵义医科大学	一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
CN102639495A (zh) *	2009-10-06	2012-08-15	百时美施贵宝公司	吡咯烷gpr40调节剂
US7939569B1 (en) *	2009-12-01	2011-05-10	Hoffmann-La Roche Inc.	Aniline analogs as glycogen synthase activators
GB2498976A (en) *	2012-02-01	2013-08-07	Prosidion Ltd	GPR119 agonists useful in the treatment of type II diabetes
EP2880034B1 (en)	2012-08-01	2016-06-22	Bristol-Myers Squibb Company	Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
RS55363B1 (sr)	2012-11-16	2017-03-31	Bristol Myers Squibb Co	Dihidropirazolni gpr40 modulatori
SG11201503562PA (en)	2012-11-16	2015-06-29	Bristol Myers Squibb Co	Dihydropyrazole gpr40 modulators
SG11201503556PA (en)	2012-11-16	2015-06-29	Bristol Myers Squibb Co	Dihydropyrazole gpr40 modulators
CA2891569A1 (en) *	2012-11-16	2014-05-22	Bristol-Myers Squibb Company	Pyrrolidine gpr40 modulators
EP3140296B1 (en) *	2014-05-07	2018-04-11	Bristol-Myers Squibb Company	Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EP3139903B1 (en)	2014-05-07	2019-07-03	Croma-Pharma Gesellschaft m.b.H.	Aqueous ophthalmic solution and method for treating dry eye syndrome
WO2015171757A1 (en)	2014-05-07	2015-11-12	Bristol-Myers Squibb Company	Pyrrolidine gpr40 modulators

2015
- 2015-05-06 EP EP15723095.4A patent/EP3140296B1/en active Active
- 2015-05-06 SG SG11201609170UA patent/SG11201609170UA/en unknown
- 2015-05-06 ES ES15723095.4T patent/ES2674531T3/es active Active
- 2015-05-06 MA MA39427A patent/MA39427B1/fr unknown
- 2015-05-06 US US14/705,524 patent/US9873679B2/en active Active
- 2015-05-06 PE PE2016002178A patent/PE20161363A1/es unknown
- 2015-05-06 PL PL15723095T patent/PL3140296T3/pl unknown
- 2015-05-06 DK DK15723095.4T patent/DK3140296T3/en active
- 2015-05-06 HU HUE15723095A patent/HUE039288T2/hu unknown
- 2015-05-06 SI SI201530232T patent/SI3140296T1/en unknown
- 2015-05-06 KR KR1020167033863A patent/KR102336370B1/ko active Active
- 2015-05-06 CA CA2948161A patent/CA2948161C/en active Active
- 2015-05-06 SM SM20180342T patent/SMT201800342T1/it unknown
- 2015-05-06 RS RS20180504A patent/RS57170B1/sr unknown
- 2015-05-06 TW TW104114493A patent/TWI659951B/zh active
- 2015-05-06 TN TN2016000444A patent/TN2016000444A1/en unknown
- 2015-05-06 AR ARP150101379A patent/AR100328A1/es unknown
- 2015-05-06 PT PT157230954T patent/PT3140296T/pt unknown
- 2015-05-06 EA EA201692037A patent/EA033250B1/ru not_active IP Right Cessation
- 2015-05-06 WO PCT/US2015/029409 patent/WO2015171722A1/en not_active Ceased
- 2015-05-06 MX MX2016013801A patent/MX378160B/es unknown
- 2015-05-06 MY MYPI2016704054A patent/MY181959A/en unknown
- 2015-05-06 TR TR2018/09633T patent/TR201809633T4/tr unknown
- 2015-05-06 HR HRP20180641TT patent/HRP20180641T1/hr unknown
- 2015-05-06 BR BR112016024936A patent/BR112016024936A2/pt not_active Application Discontinuation
- 2015-05-06 AU AU2015256120A patent/AU2015256120B2/en active Active
- 2015-05-06 JP JP2016566651A patent/JP6483156B2/ja active Active
- 2015-05-06 NZ NZ727146A patent/NZ727146A/en unknown
- 2015-05-06 CN CN201580022579.4A patent/CN106458976B/zh active Active
2016
- 2016-10-12 PH PH12016502034A patent/PH12016502034B1/en unknown
- 2016-11-01 IL IL248668A patent/IL248668B/en active IP Right Grant
- 2016-11-07 CL CL2016002809A patent/CL2016002809A1/es unknown
2017
- 2017-12-13 US US15/840,198 patent/US20180099949A1/en not_active Abandoned
2018
- 2018-05-23 CY CY20181100547T patent/CY1120340T1/el unknown
- 2018-12-06 US US16/211,848 patent/US10717725B2/en active Active
2020
- 2020-06-08 US US16/895,058 patent/US20200299267A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA033250B1 (ru)	2019-09-30
US20190112293A1 (en)	2019-04-18
PE20161363A1 (es)	2016-12-17
ES2674531T3 (es)	2018-07-02
KR102336370B1 (ko)	2021-12-06
MY181959A (en)	2021-01-15
CA2948161A1 (en)	2015-11-12
PT3140296T (pt)	2018-06-27
RS57170B1 (sr)	2018-07-31
KR20160147049A (ko)	2016-12-21
TN2016000444A1 (en)	2018-04-04
AU2015256120A1 (en)	2016-12-22
SI3140296T1 (en)	2018-06-29
EP3140296A1 (en)	2017-03-15
DK3140296T3 (en)	2018-07-23
AU2015256120B2 (en)	2019-03-28
TR201809633T4 (tr)	2018-07-23
MX2016013801A (es)	2017-03-09
TWI659951B (zh)	2019-05-21
AR100328A1 (es)	2016-09-28
MX378160B (es)	2025-03-10
EP3140296B1 (en)	2018-04-11
MA39427A1 (fr)	2017-11-30
MA39427B1 (fr)	2018-09-28
CN106458976B (zh)	2020-05-22
BR112016024936A2 (pt)	2017-08-15
JP6483156B2 (ja)	2019-03-13
US20150322044A1 (en)	2015-11-12
EA201692037A1 (ru)	2017-06-30
CN106458976A (zh)	2017-02-22
IL248668B (en)	2019-09-26
HUE039288T2 (hu)	2018-12-28
PL3140296T3 (pl)	2018-08-31
TW201625585A (zh)	2016-07-16
US10717725B2 (en)	2020-07-21
PH12016502034A1 (en)	2017-01-09
HRP20180641T1 (hr)	2018-06-01
WO2015171722A1 (en)	2015-11-12
CY1120340T1 (el)	2019-07-10
CL2016002809A1 (es)	2017-03-24
US20180099949A1 (en)	2018-04-12
NZ727146A (en)	2020-01-31
US9873679B2 (en)	2018-01-23
IL248668A0 (en)	2017-01-31
US20200299267A1 (en)	2020-09-24
JP2017514856A (ja)	2017-06-08
SG11201609170UA (en)	2016-12-29
CA2948161C (en)	2020-10-27
PH12016502034B1 (en)	2022-03-23

Publication	Publication Date	Title
HUS2100037I1 (hu)	2021-10-28	Vegyületek gerinc eredetû izomsorvadás kezelésére
IL248668B (en)	2019-09-26	Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EP3212233A4 (en)	2018-04-18	Combination therapy for treatment of disease
EP3227330A4 (en)	2018-10-31	Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
ZA201703112B (en)	2019-06-26	Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
IL249502A0 (en)	2017-02-28	Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
EP3115012A4 (en)	2017-11-08	Treatment instrument for endoscope
SMT202100082T1 (it)	2021-03-15	Composti eteroarilici per il trattamento di malattie oftalmiche
SG11201705194XA (en)	2017-07-28	Pharmaceutical composition for treating diabetes
IL270199A (en)	2019-12-31	Peptides for the treatment of diabetes
IL248670A0 (en)	2017-01-31	Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
HUE070257T2 (hu)	2025-05-28	Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
EP3096775A4 (en)	2017-10-11	Socs mimetics for the treatment of diseases
GB201403996D0 (en)	2014-04-23	Traditional chinese medicine composition for the treatment of diabetes
EP3145525A4 (en)	2018-03-07	Use of microperoxidases for the treatment of carboxyhemoglobinemia
ZA201804588B (en)	2019-09-25	Pharmaceutical formulations for the treatment of diabetes
SG11201703330YA (en)	2017-05-30	Iminosugars useful for the treatment of viral diseases
EP3184055A4 (en)	2018-04-04	Medical treatment instrument
SMT202300015T1 (it)	2023-03-17	N,n-bis-2-mercaptoetil isoftalammide per il trattamento delle malattie neurodegenerative
PT3166604T (pt)	2021-02-09	Agentes para o tratamento de doenças infeciosas retrovirais
AU2015904246A0 (en)	2015-11-05	Treatment of diabetes
AU2016901862A0 (en)	2016-06-02	Treatment of diabetes
HK1238246A1 (en)	2018-04-27	Iminosugars useful for the treatment of viral diseases
HK1238246A (en)	2018-04-27	Iminosugars useful for the treatment of viral diseases